1.TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers - PMC (nih.gov)
2.SCG Presented Preclinical Data in an Oral Presentation at ASGCT 2024 Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against HPV-associated Cancers-SCG Star Handset (scgcell.com)